- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:18 | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | 205 | GlobeNewswire (Europe) | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| 09.09. | Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 02.09. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 02.09. | Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study | 6 | RTTNews | ||
| 26.08. | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 1 | Investing.com | ||
| 06.08. | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 06.08. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.07. | JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data | 2 | Investing.com | ||
| 08.07. | Upstream Bio startet Phase-2-Studie für COPD-Medikament Verekitug | 1 | Investing.com Deutsch | ||
| 08.07. | Upstream Bio begins phase 2 COPD trial for verekitug | 1 | Investing.com | ||
| 08.07. | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | 208 | GlobeNewswire (Europe) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| 15.06. | Upstream Bio: Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor | 3 | GlobeNewswire (USA) | ||
| 05.06. | Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 | 1 | GlobeNewswire (USA) | ||
| 20.05. | Upstream Bio Appoints Stacy Price As CTO | 1 | RTTNews | ||
| 20.05. | Upstream Bio names new chief technology officer | 1 | Investing.com | ||
| 20.05. | Upstream Bio Appoints Stacy Price as Chief Technology Officer | 142 | GlobeNewswire (Europe) | WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
| 06.05. | Upstream Bio, Inc. reports Q1 results | 3 | Seeking Alpha | ||
| 06.05. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 18,620 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 6,245 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| IMMUNOVANT | 16,060 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| NUVALENT | 84,84 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 42,655 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 6,174 | +1,71 % | adidas, Evotec, Gerresheimer, Hensoldt, TeamViewer, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,915 | 0,00 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
| QIAGEN | 37,435 | -0,49 % | ROUNDUP/Aktien Frankfurt Eröffnung: Moderate Verluste - Richtungssuche | FRANKFURT (dpa-AFX) - Nach den leichten Gewinnen vom Vortag haben die Anleger am deutschen Aktienmarkt am Donnerstag wieder etwas auf die Bremse getreten. "Die Richtungssuche geht weiter", konstatierte... ► Artikel lesen | |
| VALNEVA | 5,005 | +9,47 % | Valneva-Aktie dreht wieder auf - das ist der Grund | Die Aktie des europäischen Impfstoff-Entwicklers steigt am Dienstag auf den höchsten Stand seit dem Bekanntwerden des Entzugs der US-amerikanischen Zulassung für das Chikungunya-Vakzin Ixchiq im August.... ► Artikel lesen | |
| DYNE THERAPEUTICS | 12,370 | 0,00 % | Dyne: Ministry Of Health In Japan Grants Orphan Drug Designation For DYNE-251 | ||
| HARMONY BIOSCIENCES | 27,640 | 0,00 % | Deep Dive Into Harmony Biosciences Holdings Stock: Analyst Perspectives (6 Ratings) | ||
| SUMMIT THERAPEUTICS | 21,155 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen | |
| RELAY THERAPEUTICS | 5,190 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,370 | 0,00 % | Mineralys completes enrollment in phase 2 sleep apnea drug trial | ||
| TREVI THERAPEUTICS | 8,950 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 17,380 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.